# A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

> **NCT01233258** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 80 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** rFVIII (BAY81-8973) on demand
- **BIOLOGICAL:** rFVIII (BAY81-8973) prophylaxis low-dose
- **BIOLOGICAL:** rFVIII (BAY81-8973) prophylaxis high-dose

## Key facts

- **NCT ID:** NCT01233258
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233258, "A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01233258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*